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Abstract 
During  the  last  decade,  a  more  detailed
knowledge of molecular mechanisms involved
in  osteoclastogenesis  has  driven  research
efforts in the development and screening of
compound libraries of several small molecules
that specifically inhibit the pathway involved
in the commitment of the osteoclast precursor
cells. Natural compounds that suppress osteo-
clast  differentiation  may  have  therapeutic
value in treating osteoporosis and other bone
erosive diseases such as rheumatoid arthritis
or  metastasis  associated  with  bone  loss.  In
ongoing  investigation  into  anti-osteoporotic
compounds  from  natural  products  we  have
analyzed the effect of Tanshinone VI on osteo-
clasts  differentiation,  using  a  physiologic
three-dimensional  osteoblast/bone  marrow
model of cell co-culture. Tanshinone VI is an
abietane diterpene extracted from the root of
Salvia  miltiorrhiza Bunge  (Labiatae),  a
Chinese traditional crude drug, ‘’Tan-Shen’’.
Tashinone  has  been  widely  used  in  clinical
practice  for  the  prevention  of  cardiac  dis-
eases, arthritis and other inflammation-relat-
ed  disorders  based  on  its  pharmacological
actions  in  multiple  tissues.  Although
Tanshinone VI A has been used as a medicinal
agent in the treatment of many diseases, its
role  in  osteoclast-related  bone  diseases
remains unknown. We showed previously that
Tanshinone VI greatly inhibits osteoclast dif-
ferentiation and suppresses bone resorption
through disruption of the actin ring; subse-
quently, we intended to examine the precise
inhibitory  mechanism  of  Tanshinone  VI  on
osteoclast  differentiating  factor.  This  study
shows, for the first time, that Tanshinone VI
prevents osteoclast differentiation by inhibit-
ing RANKL expression and NFkB induction.
The  strength  and  integrity  of  the  human
skeleton  depends  on  a  delicate  equilibrium
between bone resorption and formation. Bone
resorption is an elementary cellular activity in
the modelling of our skeleton during growth
and development. Later in life a most impor-
tant physiological process in the skeleton is
bone remodelling, which is locally initiated by
resorption. During remodelling bone resorp-
tion  is  coupled  to  new  bone  formation  that
ensures renewal of bone with only minor local
and temporary bone loss. Cells responsible for
bone resorption and subsequent bone forma-
tion are osteoclasts and osteoblasts, respec-
tively.
The osteoclast is derived from the pluripo-
tent hematopoietic stem cell, which gives rise
to a myeloid stem cell that can further differ-
entiate  into  megakaryocytes,  granulocytes,
monocytes/macrophages and osteoclasts. The
respective bone resorbing and forming actions
of osteoclasts and osteoblasts are finely cou-
pled, so that in a healthy adult the bone mass
remains  remarkably  stable.  Imbalances
between  osteoclast  and  osteoblast  activities
can  arise  from  a  wide  variety  of  hormonal
changes or perturbations of inflammatory and
growth  factors,  resulting  in  postmenopausal
osteoporosis,  Paget’s  disease,  lytic  bone
metastases, or rheumatoid arthritis, leading
to  increased  bone  resorption  and  crippling
bone damage.
1 Remarkable progress has been
made  in  recent  years  on  elucidating  the
molecular mechanisms of osteoclast differen-
tiation and activation, especially the discovery
of  an  osteoclast  differentiation  factor,  i.e.
receptor activator for nuclear factor ʺB ligand
(RANKL).
2
RANKL, a novel member of tumour necrosis
factor (TNF) family of cytokines, is produced
in various tissues and is especially abundant-
ly expressed in bone and in lymphoid tissues.
3
RANK/RANKL  interaction  on  the  surface  of
osteoclasts and their precursor cells triggers
signalling  through  several  enzymatic  path-
ways, leading to activation some adaptor pro-
teins such as TRAF-6,
4 TAB-2, IRAK 1-3 and
Src, that activate Akt, AP-1 and NF-kB.
5 Within
these transcription factors, RANKL specifical-
ly  induces  expression  of  the  NFAT  family
member NFATc1, which is the master regula-
tor  of  OC  differentiation.  This  induction  is
dependent  on  NF-ʺB  pathway  via  RANKL-
RANK stimulation.
6 The NF-ʺB signal trans-
duction pathway has long been recognized as
critical for osteoclast development and func-
tion
7,8 and double knock-out of p50 and p52 NF-
ʺB subunits leads to osteoporosis, due to a
severe defect in osteoclast differentiation in
these mice.
7 Consequently, this pathway regu-
lates many osteoclast specific genes, such as
tartrate-resistant  acid  phosphatase  (TRAP),
which  results  in  the  activation  of  enzymes
that  mediate  the  secretion  of  various  sub-
stances,  thus  leading  to  the  final  step  of
matrix and mineral dissolution.
9 During the
last  decade,  a  more  detailed  knowledge  of
these  molecular  mechanisms  involved  in
osteoclastogenesis has driven research efforts
in  the  development  and  screening  of  com-
pound libraries of several small molecules that
specifically  inhibit  these  pathways.  Natural
compounds suppressing osteoclast differenti-
ation may have therapeutic value in treating
osteoporosis and other bone erosive diseases,
such as rheumatoid arthritis associated with
bone loss.
10 In ongoing investigation into anti
bone  resorption  compounds  from  natural
products,  we  have  analyzed  the  effect  of
Tanshinone VI, an abietane diterpene extract-
ed from the root of Salvia miltiorrhiza Bunge
(Labiatae), a Chinese traditional crude drug,
‘’Tan-Shen’’. Tashinone has been widely used
in clinical practice for the prevention of car-
diac diseases, arthritis and other inflamma-
tion-related disorders based on its pharmaco-
logical actions in multiple tissues. Salvia mil-
tiorrhiza extract  contains  several  diterpene
derivatives,  such  as  Tanshinone  IIA
11-15 and
Tanshinone  VI  (Tan)  (Figure  1)  that  have
some  pharmacological  activities  on  cardiac
fibroblasts,  cardiomyocytes  etc.;  however,
their effects on osteoclast differentiation and
function are unknown.
The crude Tanshinone VI used in the pres-
ent investigation was obtained by extraction
with ethanol-n-hexane (1:1, v/v) from S. milti-
orrhiza Bunge. Preparative HSCCC with the
two-phase solvent systems A composed of n-
hexane-ethanol-water (10:5.5:4.5, v/v) and B
composed of n-hexane-ethanol-water (10:7:3,
v/v) was successfully performed in a stepwise
elution  yielding  six  relatively  pure  diter-
penoids from 300 mg of the crude extract in a
single run.
To test the effect of Tanshinone VI on osteo-
clast  differentiation  we  used  a  physiologic
three-dimensional  osteoblast/bone  marrow
model  of  cell  co-culture.
16 Osteoclasts  were
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identified  in  the  mixed  population  derived
from  a  murine  co-culture  model,  developed
using  monocyte-macrophage  cell  line  RAW
264.7 and osteoblast cell line type CRL 12257,
that form mature osteoclasts within 4 days in
absence of exogenous cytokines.
16 In order to
examine viabilities of cells involved in co-cul-
ture model in response to Tanshinone VI, cells
were treated with 10 ng/mL for 4 days with
Tanshinone  VI,  according  with  previous
works.
14,15 The  effect  of  Tanshinone  VI
revealed  a  significant  inhibitory  effects  on
osteoclast  differentiation  (Figure  2  A-A1),
demonstrated as an inhibitory effect on for-
mation  of  TRAP-positive  multinucleated
osteoclasts  (Figure  2,  B-B1).  In  order  to
exclude this indirect effect, we used the cul-
ture  condition  under  which  osteoclasts  are
differentiated  from  bone  marrow-derived
macrophages in the presence of M-CSF plus
RANKL without the support of osteoblast cells
(data not shown). In this culture, the inhibito-
ry effect of Tanshinone VI on osteoclastogene-
sis was also observed. With the aim to investi-
gate the effect of Tanshinone VI on functional-
ity of osteoclast, we have analyzed by immuno-
histochemistry the formation of the actin ring
that  is  a  pre-requisite  for  osteoclasts  bone
resorption.
16-18 Staining F-actin with phalloidin
showed a ring structure in mature osteoclasts
purified from control co-culture characterized
by clear margin (Figure 2 C, yellow arrow). On
the opposite, Tanshinone VI treatment affects
the actin ring structure, resulting as a loose
and fuzzy structure (Figure 2, C1).
Looking at the expression of RANKL and Nf
ʺB,  it  was  found  that  both  significantly
decreased  in  co-culture  treated  with
Tanshinone VI in respect of vehicles (Figure,
3). These results suggest that Tanshinone VI
may affect RANKL-induced signalling involved
in  osteoclastogenesis.  Based  on  these  data,
we hypothesize that pharmacological suppres-
sion  of  NF-ʺB  and  RANKL  induced  by
Tanshinone  VI  in  vivo may  be  an  effective
approach  to  improve  bone  loss  suppressing
osteoclastic bone resorption.
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